Testing Solutions to Advance Your COVID-19 Clinical Trials

Developing a vaccine or therapeutic in response to the outbreak of the 2019 Novel Coronavirus (COVID-19) requires a laboratory with significant technical and cross-functional experience. Covance Central Laboratories is prepared to support your COVID-19 studies.

Capabilities Specific to COVID-19

Several assays that are specific to COVID-19 are undergoing expedited validation to meet clinical trial testing standards:



Viral Load Testing by qPCR

- Built on the LabCorp Emergency Use Authorization Diagnostics, which was made available in early March
- Now available for clinical trials

Viral Neutralization Assay

- Expected availability for clinical trials in early Q3 2020

COVID-19 Screening/Rapid Detection by PCR

- Validation will begin immediately following FDA approval of the GeneXpert® assay from Cepheid
- Expected availability for clinical trials 3 weeks following reagent kit availability

Antibody Detection by ELISA

- Validation has been initiated for IgG and IgA; expected availability for clinical trials in June 2020
- Additional evaluations of IgM and quantitative serology tests will begin immediately upon availability of kits and reagents and be completed within 6-8 weeks

Assay panels that can be used to exclude other respiratory illnesses are already validated to meet clinical trial testing standards.

- BioFire® FilmArray® Respiratory Panel rules out 21 different respiratory illnesses. BioFire Diagnostics is adding COVID-19 to the panel; expanded panel expected to be available for clinical trials 3-4 weeks following reagent kit availability.

Protocol-Specific Assay Customization

Expedited customization of existing assays as required for your protocol and/or molecule:

- Viral functional assays
- ELISpot
- Flow cytometry
- Infectivity

COVANCE®

Extensive Assay Menu

Comprehensive immunology and safety test menu already available for clinical trials:

- Cytokine panels
- Kidney function
- Liver function

Experience in China

- Access a full suite of immunology, flow cytometry and safety testing at the new, state-of-the-art Shanghai R&D Center that opened in 2019
- Receive global guidance and local expertise that draws on 20+ years of experience
- Expect both scientific and operational support

World-Class Global Logistics

Ensure on-time, in-stability transportation and draw on the expertise of 50+ global logistics experts. With multi-layer contingency plans in place, we work around the clock so samples arrive on time.

Covance Global Vaccine Experience and Capabilities

In the past 5 years:

65 protocols

45 countries

1,049 sites

38,453 patients

Clinical Indications/ Target Pathogens	**Respiratory** (diphtheria, pandemic flu, pertussis, pneumococcal, RSV, seasonal flu, strep A/B, tuberculosis)	**Enteric** (cholera, *C. difficile*, *E. coli*, norovirus, rotavirus, *Shigella*, typhoid)	**Sexually Transmitted** (chlamydia, CMV, hepatitis B, herpes, HIV, HPV)	**Vector/ Zoonotic** (Chikungunya, dengue, malaria, West Nile, Zika, various genetically modified vectors)	**Other** (hepatitis, HIB, meningococcal, MMRV, rubella, *Staph. aureus*, tetanus)

GeneXpert® is a trademark of Cepheid
BioFire® FilmArray® is a trademark of BioFire Diagnostics LLC

Learn more at **www.covance.com**

Covance is a business segment of LabCorp, a leading global life sciences company, which provides contract research services to the drug, medical device and diagnostic, crop protection and chemical industries. COVANCE is a registered trademark and the marketing name for Covance Inc. and its subsidiaries around the world.

www.covance.com

© Copyright 2020 Covance Inc. SSCLS057-0420

COVANCE®